Halozyme Therapeutics (HALO) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $124.83 --0%
Revenue Growth %: +37.6%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.6%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $58.95 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- Allegion plc (ALLE) Tops Q3 EPS by 10c ; Offers Guidance
- Qiagen posts $548M in Q3 2026 net sales amid pending EQT deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
